Drug Trial Radar · NCT06834230
Effect of Dotinurad in Hyperuricemia With Hypertension
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Mar 28, 2025
Primary completion
Jul 31, 2027
Study completion Mar 31, 2030
Sponsor
- Lead sponsor
- Saga UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The effect of dotinurad on CAVI (cardio-ankle vascular index) will be compared with that of febuxostat in patients with hyperuricemia complicated by hypertension.
Conditions
- Hyperuricemia or Gout
- Hypertension
Interventions
DotinuradDrug
Start at 0.5 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (2 mg once daily).
FebuxostatDrug
Start at 10 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (40 mg once daily).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in CAVITime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Saga University
Saga, Saga-ken, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.